www.klinickafarmakologie.cz / Klin Farmakol Farm. 2024;38(2):72-75 / KLINICKÁ FARMAKOLOGIE A FARMACIE 75 PŘEHLEDOVÉ ČLÁNKY Klinický aspekt poskytovania lekárenskej starostlivosti vo verejných lekárňach V príprave je odborná príprava na realizáciu očkovania dospelých pacientov proti chrípke (7) v rámci preventívneho programu na podporu zaočkovanosti populácie na Slovensku. Záver Je zrejmé, že súčasné globálne výzvy v zdravotníctve formujú aj obsah a rozsah poskytovania lekárenskej starostlivosti vo verejných lekárňach celosvetovo. V súčasnosti dokáže lekárnik vďaka svojej odbornej zdatnosti a profesionálnej pripravenosti čeliť týmto výzvam a plnohodnotne participovať na starostlivosti v prospech verejného zdravia. LITERATÚRA 1. Farris KB, Fernandez-Llimos F, Benrimoj SCh. Pharmaceutical Care in Community Pharmacies: Practice and Research from Around the World. Annals of Pharmacotherapy. 2005;39(9):1539-1541. 2. PGEU Annual Report. Chronic medicine shortages affect patients’ health and pharmacy practice. [Internet]. 2023. p. 2-5 [cited 2024 January 17]. Available from: https://www.pgeu. eu/wp-content/uploads/2024/03/Annual-Report-2023-Version 3.2 (pgeu.eu)-Version-FINAL.pdf. 3. The World Health Organisation Cardiovascular diseases Risk Chart Working Group World. Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lacet Glob. Health. 2019;7:1332-1345. 4. World Health Organisation. Global strategy and action plan on ageing and health. [Internet]. Geneva: World Health Organization; 2017 [cited January 19]. Available from: http://www. iris.who.int/bitstream/handl/10665/329960/9789241513500. 5. Garattini S, Natsis Y, Banzi R. Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies. Front Pharmacol. 2021;12:685604. 6. Chang ES, Kannoth S, Levy S, et al. Global reach of ageism on older persons’ health: A systematic review. PLoS One. 2020;15(1):e0220857. 7. Zákon č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach. 8. Svarstad BL, Kotchen JM, Shireman TI, et al. Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. J Am Pharm Assoc. 2013;53:520-529. 9. Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, et al. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract (Granada). 2017;15(2):919. 10. Via-Sosa MA, Toro C, Travé P, March MA. Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study. BMC Public Health. 2014;22(14):487. 11. Willis A, Rivers P, Gray LJ, et al. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS One. 2014;9(4):e91157. 12. Štandardný postup pre výkon prevencie kardiovaskulárnych ochorení v podmienkach verejných lekární. ŠP 042. Vestník Ministerstva zdravotníctva SR. Osobitné vydanie. 15. 1. 2023. Ročník 71. 13. Štandardný postup pre výkon prevencie ochorení pečene v podmienkach verejných lekární. ŠP 056. Vestník Ministerstva zdravotníctva SR. Osobitné vydanie. 15. 1. 2024. Ročník 72. 14. Štandardný postup pre výkon skríningu a prevencie (pre) obezity v podmienkach verejných lekární. ŠP 055. Vestník Ministerstva zdravotníctva SR. Osobitné vydanie. 15. 1. 2024. Ročník 72. 15. Štandardný postup pre výkon skríningu porúch glukózového metabolizmu a diabetes mellitus 2. typu v podmienkach verejných lekární. ŠP 057. Vestník Ministerstva zdravotníctva SR. Osobitné vydanie. 15. 1. 2024. Ročník 72. 16. Štandardný postup pre manažment pacientov s podozrením na akútne infekcie horných dýchacích ciest v podmienkach verejných lekární. ŠP 300. Vestník Ministerstva zdravotníctva SR. Osobitné vydanie. 15. 1. 2024. Ročník 72. 17. Teka NT, Baye AM. Counseling practice of community pharmacists for diabetes mellitus patients in Addis Ababa, Ethiopia. BMC Res Notes. 2018;11(1):700. 18. Al Hamarneh YN, Marra C, Gniadecki R, et al. RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study. BMJ Open. 2021;11(3):e043612. 19. Brown TJ, Todd A, O’Malley C, et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. BMJ Open. 2016;6(2):e009828. 20. Sharma S, Kc B, Alrasheedy AA, et al. Impact of community pharmacy-based educational intervention on patients with hypertension in Western Nepal. Australas Med J. 2014;7(7):304-313. 21. Huete L, Manzano-Lista FJ, Aránguez I, Fernández-Alfonso MS. Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients. Int J Clin Pharm. 2019;41(4):1099-1109. 22. Marfo AFA, Owusu-Daaku FT. Exploring the extended role of the community pharmacist in improving blood pressure control among hypertensive patients in a developing setting. J Pharm Policy Pract. 2017;21(1):39. 23. Ha M, Furman A, Al Rihani SB, et al. Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Programs of All-Inclusive Care for the Elderly. J Am Geriatr Soc. 2022;70(11):3230-3238. 24. Martin P, Tamblyn R, Benedetti A, et al. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018;320(18):1889-1898. 25. Heikkilä JM, Parkkamäki S, Salimäki J, et al. Community pharmacists’ knowledge of COPD, and practices and perceptions of medication counseling of COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2065-2074. 26. Rickles NM, Skelton JB, Davis J, Hopson J. Cognitive memory screening and referral program in community pharmacies in the United States. Int J Clin Pharm. 2014;36(2):360-367. 27. Arikawe O, Morrissey H, Ball P. Community pharmacy brief screening intervention to improve health outcomes for patients diagnosed with chronic diseases. J. Adv. Pharm. Educ. Res. 2022;12(3):1-8. 28. Brain J, Tully PJ, Turnbull D, et al. Risk factors for dementia in the context of cardiovascular disease: A protocol of an overview of reviews. PLoS One. 2022;17(7):e0271611. Published 2022 Jul 21. doi:10.1371/journal.pone.0271611. 29. Harasani K, Xhafaj D, Lekaj A, et al. Screening for mild cognitive impairment among older Albanian patients by clinical pharmacists. Int J Pharm Pract. 2021;29(2):189-191. 30. Climent MT, Pardo J, Muñoz-Almaraz FJ, et al. Decision Tree for Early Detection of Cognitive Impairment by Community Pharmacists. Front Pharmacol. 2018;9:1232. 31. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community Pharmacist-Initiated Screening Program for Osteoporosis: Randomized Controlled Trial. Osteoporos Int. 2010;21:391398. doi:10.1007/S00198-009-0977-Z. 32. Giles JT, Kennedy DT, Dunn EC, et al. Results of a Community Pharmacy-Based Breast Cancer Risk-Assessment and Education Program. Pharmacotherapy. 2001;21:243-253. doi:10.1592/PHCO.21.2.243.34100. 33. Potter MB, Gildengorin G, Wang Y, Wu M, Kroon L. Comparative Effectiveness of Two Pharmacy-Based Colorectal Cancer Screening Interventions during an Annual Influenza Vaccination Campaign. Journal of the American Pharmacists Association. 2010:50. 34. Hughes C, Winterstein A, McElnay J, et al. Improving the Well-Being of Elderly Patients via Community Pharmacy-Based Provision of Pharmaceutical Care: A Multicentre Study in Seven European Countries. Drugs Aging. 2001;18:63-77. 35. West LM, Cordina M. Educational Intervention to Enhance Adherence to Short-Term Use of Antibiotics. Res Social Adm Pharm. 2019;15:193-201. doi:10.1016/J.SAPHARM.2018.04.011. 36. Usami T, Hashiguchi M, Kouhara T, et al. Impact of Community Pharmacists Advocating Immunization on Influenza Vaccination Rates among the Elderly. Yakugaku Zasshi. 2009;129:1063-1068. 37. Matejka P, Švec P, Seginko J, et al. Možnosti stanovenia rizikových faktorov aterosklerózy v podmienkach verejnej lekárne. Slov. Revue. 2003;13(2-3):62-64. 38. Matejka P, Švec P, Seginko J, et al. Záujem návštevníkov verejných lekární o meranie základných parametrov určujúcich riziko rozvoja aterosklerózy v lekárni. Farm Obzor. 2004;73(8):203-208. 39. Matejka P, Švec P, Seginko J. Effect of pharmacy-based point of care screening and counselling on patient’s global coronary risk Pharmacy World & Science. 2005;27(2):A27-A28. 40. Matejka P, Švec P. Metodická príručka pre poskytovanie biochemických vyšetrení v lekárni. Bratislava: Univerzita Komenského, Farmaceutická fakulta; 2014: 34 s. 41. Hwang AY, Gums TH, Gums JG. The benefits of physician-pharmacist collaboration. J Fam Pract. 2017;66(12):E1-E8. PMID: 29202145. 42. Kelly DV, Bishop L, Young S, et al. Pharmacist and physician views on collaborative practice: Findings from the community pharmaceutical care project. Can Pharm J (Ott). 2013;146(4):218-226. 43. Waszyk-Nowaczyk M, Guzenda W, Kamasa K, et al. Cooperation Between Pharmacists and Physicians – Whether It Was Before and is It Still Ongoing During the Pandemic? J Multidiscip Healthc. 2021;14:2101-2110. 44. Macekova Z, Fazekas T, Stanko P, et al. Cognitive screening within advanced pharmaceutical care in elderly patients with suspected metabolic syndrome. Int. J. Gerontol. 2022;16:355-360. 45. Macekova Z, Krivosova M, Fazekas T, et al. Short cognitive screening in elderlies as a part of advanced pharmaceutical care in Slovak community pharmacies – The pilot study KOGNIMET-SK. Eur. Pharm. J. 2022;69:37-42. 46. Macekova Z, Fazekas T, Krivosova M, et al. Identification of a Link between Suspected Metabolic Syndrome and Cognitive Impairment within Pharmaceutical Care in Adults over 75 Years of Age. Healthcare. 2023;11(5):718. 47. Jin H, Huang Y, Xi X, et al. Exploring the training of pharmacists oriented to the demands for clinical pharmacy services: from the perspective of physicians. BMC Med Educ. 2023;23:357. https://doi.org/10.1186/s12909-023-04353-7. 48. Alfian SD, van Boven JFM, Abdulah R, et al. Effectiveness of a targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled trial. Br J Clin Pharmacol. 2021;87(4):2032-2042.
RkJQdWJsaXNoZXIy NDA4Mjc=